Blueprint Medicines To Be Acquired by Sanofi for $9.5 Billion
Deal News | Jun 02, 2025 | Goodwins
Blueprint Medicines Corporation has entered into a definitive agreement to be acquired by Sanofi for approximately $9.5 billion, including contingent value rights. Sanofi will pay $129 per share of Blueprint’s common stock in an all-cash transaction. Additionally, stockholders will receive non-tradable contingent value rights (CVRs) entitling them to potential milestone payments based on the achievement of certain development and regulatory endpoints for BLU-808. The deal is subject to customary closing conditions and regulatory approvals and is expected to conclude in the third quarter of 2025. Blueprint Medicines, a NASDAQ-listed biopharmaceutical company, focuses on creating life-changing drugs for allergy/inflammation and oncology/hematology. They have a successful track record with two approved medicines, including AYVAKIT/AYVAKYT. Goodwins provided legal advisory services for the transaction.
Sectors
- Biopharmaceuticals
- Mergers and Acquisitions
Geography
- United States – Blueprint Medicines is a U.S.-based company listed on the NASDAQ, indicating its primary operations and market are in the United States.
- Global – Sanofi is a multinational company and the transaction has implications on a global scale in the pharmaceutical industry.
Industry
- Biopharmaceuticals – The article centers on Blueprint Medicines, a biopharmaceutical company developing treatments for severe diseases, indicating its relevance to the biopharmaceutical industry.
- Mergers and Acquisitions – The transaction between Sanofi and Blueprint Medicines is a significant M&A event, which is a key part of the investment and corporate finance industry.
Financials
- 9.5 billion – Total equity value of the transaction on a fully diluted basis, including contingent value rights.
- 129 – Cash payment per share of Blueprint common stock.
- 2.00 and 4.00 – Potential milestone payments per CVR for achieving certain development and regulatory milestones for BLU-808.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Blueprint Medicines Corporation | Target | Company | A global biopharmaceutical company engaged in the development of therapies for allergy/inflammation and oncology/hematology. |
| Sanofi | Bidding Company | Company | A global healthcare leader that is acquiring Blueprint Medicines. |
| Goodwins | Legal Advisor | Company | Provided legal advisory services to Blueprint Medicines in the acquisition by Sanofi. |